The journey an established technology company is making into the life sciences market to improve drug screening.
Lab work
The journey of drug development is a long one, taking 10 - 20 years, costing billions in funding and offering less than 10% of success when entering phase I of clinical trials. Even finding a drug candidate in the pre-clinical phase is a tedious screening process in which hundreds of thousands of compounds are tested against potential disease targets.
Now, an established technology company is looking to make the process for drug screening less intensive for those working in the lab. Entering a new market is never easy, but that’s exactly what LPKF is doing with its foray into life sciences under the brand ARRALYZE.